Arcellx
ACLX----
Arcellx (ACLX)
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Arcellx Analyst Rating
View MoreForecast & Rating
Apr 2, 2026Price forecast
$112.85-1.93%
Forecast & RatingHold
18analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Apr 29 at 10:34 AM
Arcellx's (ACLX) "Neutral" Rating Reiterated at Cantor Fitzgerald
- Tip Ranks · Apr 28 at 03:55 PM
Arcellx Acquired in Cash-and-CVR Deal, Going Private
- Market Beat · Apr 28 at 05:02 AM
Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist Financial
- StockTitan · Apr 27 at 11:45 PM
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | ACLX Stock News
- StockTitan · Apr 16 at 11:30 PM
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | GILD Stock News
- Simplywall · Apr 10 at 01:02 AM
Gilead’s Deal Spree Shifts Pipeline Toward Oncology And Potential Upside
